drugset
Drugs / Second generation humanized CAR-T cells
last change Apr 2025 re-read 3 minutes ago

Second generation humanized CAR-T cells

Cell therapy targets CD19 via depletion

Developed for
acute lymphoblastic leukemia
Investigated by
Jingzhou Central Hospital · People Hospital Of Yichang · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan Sian Medical Technology Co., Ltd · Xiangyang Central Hospital

Trials 1

today NCT04008251 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04008251 May 2019 → Jul 2022 acute lymphoblastic leukemia Wuhan Sian Medical Technology Co., Ltd Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Second generation humanized CAR-T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04008251 ↗
Action Deplete “Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) have the capabilities to recognize tumor associated antigen and kill tumor cells specifically.” NCT04008251 ↗
Modality Cell therapy “Chimeric Antigen Receptor T-cell (CAR-T) therapy” PMID 40195173 ↗ Apr 2025
Target CD19 “Chimeric antigen receptor T (CAR-T) cells targeting CD19” PMID 35799791 ↗ Jun 2022